Extemporaneous compounding of medicinal cannabis was approved in October 2017 enabling appropriately licensed pharmacies to produce a cannabis medicine on a medical prescription.
This webinar will:
* Differentiate between the compounding pathway and all other access pathways for medicinal cannabis prescribing.
* Review the quality standards for compounded and manufactured cannabis medicines.
* Discuss the prescribing requirements for compounded medicinal cannabis.
Antony Condina is Green Dispensary Compounding’s senior compounding pharmacist and the CEO of pharmaceutical manufacturer GD Pharma. Bringing years of expertise in both the manufacturing and compounding fields, he will provide a detailed insight into the way in which the compounding access pathway is able to meet a need for cannabis medicines including medico-legal considerations for prescribers and patient benefits. This will be followed by a Q+A session.
Considering prescribing medicinal cannabis? Join Antony to hear about a unique pathway to patient access.
Presenter: Antony Condina